Healthcare Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

 

INDUSTRY
Healthcare

RELEASE DATE
23-Aug-2010
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
9561-00-AC-00-00
SKU
HC00601-NA-MR_04074
Yes
SHARE

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
Published on: 23-Aug-2010 | SKU: HC00601-NA-MR_04074

Need more details?

$1,500.00

$1,125.00 save 25 %

DownloadLink
Need more details?

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.

This week's issue:


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

08 Oct 2026   |   Global   |   Frost Radar

Frost Radar: Endoscopy Device Technology Ecosystem, 2026

The endoscopy device market is advancing toward higher-quality visualization and improved clinical decision-making, with innovation across 4K ultrahigh-definition display systems, image-enhanced endoscopy, and computer-aided detection systems. Advanced visualization is evolving through improvements ...

07 Oct 2026   |   Global   |   Technology Research

Growth Opportunities in Image-Guided Cancer Ablation Systems

Image-guided cancer ablation systems are minimally invasive medical technologies that use real-time imaging to accurately guide the placement of an ablation device into a tumor, enabling localized destruction of cancerous tissue while minimizing damage to surrounding healthy structures.The increasin...

06 Oct 2026   |   Global   |   Technology Research

Trends in Laboratory Automation, Global, 2021–2025

This research study provides a comprehensive assessment of the recent trends, technological advancements, and strategic developments shaping the global laboratory automation industry. The analysis traces the evolution of laboratory automation from task-specific automation systems to integrated, inte...

05 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026

The point-of-care ultrasound imaging industry is undergoing a fundamental transformation from equipment-intensive ultrasound to portable, handheld, wireless, AI-enabled, and connected point-of-care solutions. Driven by the need for rapid bedside diagnosis and decentralized healthcare delivery, speci...

25 Sep 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Diagnostic Solutions, and Implantables

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantables.The issue features advanced medical devices such as peritoneal dialysis fluid system, cold sterilization-based au...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for BRAHMS, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Industries Healthcare
WIP Number 9561-00-AC-00-00
Is Prebook No

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00601-NA-MR_04074